Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also decreasing need for ...

Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...

"Amgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNP" was originally created and published by ...

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

THE TRICK FOR GOING DOWNHILL IS JUST KEEP YOUR WEIGHT FORWARD. ALL PART OF AN OUTING PLANNED BY WAYPOINT ADVENTURE. SO THEY’RE LEARNING TECHNIQUES ABOUT HOW TO HOLD YOURSELF IN POSITION ON THE ...

Ord Minnett analyst Milo Ferris maintained a Buy rating on Waypoint REIT Ltd. (WPR – Research Report) today and set a price target of A$2.72.

Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery ...